GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, commonly known as GSK, is a leading global healthcare company headquartered in India. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since made significant strides in the pharmaceutical industry, focusing on research and development across various therapeutic areas, including vaccines, oncology, and respiratory health. With a strong presence in major operational regions such as Europe, North America, and Asia, GSK is renowned for its innovative core products, including vaccines like Shingrix and treatments for chronic diseases. The company’s commitment to scientific excellence and patient-centric solutions has solidified its market position, making it a trusted name in healthcare. GSK continues to achieve notable milestones, driving advancements that enhance global health outcomes.
DitchCarbon Score
How does GlaxoSmithKline Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GlaxoSmithKline Pharmaceuticals Limited's score of 14 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GlaxoSmithKline Pharmaceuticals Limited's reported carbon emissions
In 2023, GlaxoSmithKline Pharmaceuticals Limited reported total carbon emissions of approximately 10,689,710 kg CO2e, comprising 486,950 kg CO2e from Scope 1 and 10,202,750 kg CO2e from Scope 2 emissions. This represents a slight increase in emissions compared to 2022, where total emissions were about 10,994,650 kg CO2e, with Scope 1 at 286,210 kg CO2e and Scope 2 at 10,708,440 kg CO2e. For 2024, GSK's emissions are projected to be around 10,732,240 kg CO2e, with Scope 1 emissions increasing to 774,320 kg CO2e and Scope 2 emissions decreasing to 9,957,920 kg CO2e. Despite these figures, GSK has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on its emissions intensity per rupee of turnover, which was reported at approximately 7.29e-09 for 2023 and 7.13e-09 for 2024, indicating a commitment to improving efficiency alongside revenue generation. Overall, GSK's emissions data highlights the ongoing challenges in reducing carbon footprints within the pharmaceutical industry, while their lack of specific reduction targets suggests a need for more defined climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 286,210 | 000,000 | 000,000 |
| Scope 2 | 10,708,440 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GlaxoSmithKline Pharmaceuticals Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
